Special Issue "Emerging Role of Immunotherapies in Cancer and Their Cardiotoxic Effects"
Deadline for manuscript submissions: 31 January 2022.
Interests: cardioprotection; heart failure; cardio-oncology; myocardial infarction; nitrite and nitric oxide signalling
Interests: biomarkers; cardio-immunology; cardioprotection; cardio-oncology; myocardial infarction
Immune checkpoint inhibition (ICI) and chimeric antigen receptor (CAR) T cell therapy are emerging immunotherapies in cancer and have improved the survival of cancer patients in recent years across various types of cancer. Adjuvant and neoadjuvant study concepts using both therapies are under development. However, both therapies cause a wide range of immune-related adverse events (irAEs), including incompletely characterized forms of cardiotoxicity. In the light of the rapidly growing number of patients receiving such therapies, there is an indispensable need to identify mechanisms of cardiotoxicity in order to prevent, reduce, and protect from such toxic effects.
We, therefore, invite investigators to contribute original research as well as review articles that focus on efforts to understand and elucidate various aspects of the mechanisms of cardiotoxicity in cancer immunotherapy, including molecular, genetic/epigenetic, and immunological findings.
Prof. Dr. Tienush Rassaf
Dr. Lars Michel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune checkpoint inhibitors
- CAR T cells
- heart failure
- cancer therapy